Full Fed. Circ. Won't Review Generics Jurisdiction Ruling
The full Federal Circuit on Monday declined to review a panel's opinion that Mylan must face patent infringement suits in Delaware federal court, handing wins to pharmaceutical companies AstraZeneca AB and...To view the full article, register now.
Already a subscriber? Click here to view full article